Deitz Galia A, Patnaik Jennifer L, Young Cara E Capitena, Ertel Monica K, SooHoo Jeffrey R, Seibold Leonard K, Kahook Malik Y, Pantcheva Mina B
Department of Ophthalmology, University of Colorado School of Medicine, Sue Anschutz-Rodgers Eye Center, 1675 Aurora Court, Aurora, CO, 80045, USA.
Adv Ther. 2023 Apr;40(4):1444-1455. doi: 10.1007/s12325-022-02409-6. Epub 2023 Jan 24.
To compare outcomes of phacoemulsification combined with endoscopic cyclophotocoagulation (phaco/ECP), first generation iStent implantation (phaco/iStent), or both (phaco/iStent/ECP) in patients with open-angle glaucoma.
A retrospective chart review was performed on patients at the University of Colorado Department of Ophthalmology. Outcomes included intraocular pressure (IOP), medication use, best corrected visual acuity (BCVA), and surgical complications were analyzed. Success was defined as IOP reduction of ≥ 20% and/or reduction by at least one glaucoma medication.
A total of 394 eyes were included in the study. There were 170 eyes (43.1%) in the phaco/ECP group, 175 eyes (44.4%) in the phaco/iStent group, and 49 eyes (12.4%) in the phaco/iStent/ECP group. The mean pre-operative IOP was 15.9 mmHg for phaco/ECP, 15.8 mmHg for phaco/iStent, and 15.2 mmHg for phaco/iStent/ECP. At 24 months, the mean IOP was 13.7 mmHg (p < 0.0001), 14.2 mmHg (p = 0.0001), and 13.0 mmHg (p = 0.0007), respectively. The mean pre-operative number of glaucoma medications was 2.0 for phaco/ECP, 1.4 for phaco/iStent, and 2.2 for phaco/iStent/ECP and at 24 months post-surgery decreased to, 1.8 (p = 0.011), 0.9 (p < 0.0001), and 1.7 (p = 0.01), respectively. The success rate at 24 months was 54.4% for phaco/ECP, 75.3% for phaco/iStent, and 55.6% for phaco/iStent/ECP.
Phacoemulsification when combined with ECP, iStent, or both, lowered IOP and glaucoma medication reliance at 24 months. The success rate for phaco/iStent was significantly higher than phaco/ECP. When iStent was added to phaco/ECP, the success rate was higher at earlier postoperative visits compared to the phaco/ECP alone.
比较超声乳化联合内镜睫状体光凝术(phaco/ECP)、第一代iStent植入术(phaco/iStent)或两者联合(phaco/iStent/ECP)治疗开角型青光眼患者的疗效。
对科罗拉多大学眼科的患者进行回顾性病历审查。分析的结果包括眼压(IOP)、药物使用情况、最佳矫正视力(BCVA)和手术并发症。成功定义为眼压降低≥20%和/或青光眼药物使用至少减少一种。
该研究共纳入394只眼。phaco/ECP组有170只眼(43.1%),phaco/iStent组有175只眼(44.4%),phaco/iStent/ECP组有49只眼(12.4%)。phaco/ECP组术前平均眼压为15.9 mmHg,phaco/iStent组为15.8 mmHg,phaco/iStent/ECP组为15.2 mmHg。在24个月时,平均眼压分别为13.7 mmHg(p < 0.0001)、14.2 mmHg(p = 0.0001)和13.0 mmHg(p = 0.0007)。phaco/ECP组术前青光眼药物平均使用数量为2.0,phaco/iStent组为1.4,phaco/iStent/ECP组为2.2,术后24个月分别降至1.8(p = 0.011)、0.9(p < 0.0001)和1.7(p = 0.01)。24个月时,phaco/ECP组成功率为54.4%,phaco/iStent组为75.3%,phaco/iStent/ECP组为55.6%。
超声乳化联合ECP、iStent或两者在24个月时可降低眼压并减少对青光眼药物的依赖。phaco/iStent的成功率显著高于phaco/ECP。与单独的phaco/ECP相比,在phaco/ECP基础上加用iStent在术后早期随访时成功率更高。